Business Description
Coherus BioSciences Inc
NAICS : 541714
SIC : 2836
ISIN : US19249H1032
Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.27 | |||||
| Equity-to-Asset | -0.23 | |||||
| Debt-to-Equity | -3.58 | |||||
| Debt-to-EBITDA | -2.75 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -3.63 | |||||
| Beneish M-Score | -0.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.66 | |||||
| 9-Day RSI | 48.97 | |||||
| 14-Day RSI | 43.79 | |||||
| 6-1 Month Momentum % | -39.31 | |||||
| 12-1 Month Momentum % | -59.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.85 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 0.55 | |||||
| Days Inventory | 203.19 | |||||
| Days Sales Outstanding | 228.41 | |||||
| Days Payable | 91.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -20.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.01 | |||||
| Operating Margin % | -88.02 | |||||
| Net Margin % | -102.86 | |||||
| FCF Margin % | -124.24 | |||||
| ROA % | -43.64 | |||||
| ROIC % | -105.03 | |||||
| ROC (Joel Greenblatt) % | -281.07 | |||||
| ROCE % | -54.16 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.14 | |||||
| EV-to-EBIT | -3.3 | |||||
| EV-to-Forward-EBIT | 7.53 | |||||
| EV-to-EBITDA | -3.38 | |||||
| EV-to-Forward-EBITDA | 7.34 | |||||
| EV-to-Revenue | 2.79 | |||||
| EV-to-Forward-Revenue | 1.47 | |||||
| EV-to-FCF | -2.18 | |||||
| Earnings Yield (Greenblatt) % | -30.3 | |||||
| FCF Yield % | -103.01 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CHRS
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coherus BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 211.072 | ||
| EPS (TTM) ($) | -2.62 | ||
| Beta | 0.8 | ||
| Volatility % | 65.85 | ||
| 14-Day RSI | 43.79 | ||
| 14-Day ATR ($) | 0.284894 | ||
| 20-Day SMA ($) | 2.2455 | ||
| 12-1 Month Momentum % | -59.88 | ||
| 52-Week Range ($) | 1.4301 - 10.9907 | ||
| Shares Outstanding (Mil) | 111.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coherus BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coherus BioSciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Coherus BioSciences Inc Frequently Asked Questions
What is Coherus BioSciences Inc(CHRS)'s stock price today?
The current price of CHRS is $2.21. The 52 week high of CHRS is $10.99 and 52 week low is $1.43.
When is next earnings date of Coherus BioSciences Inc(CHRS)?
The next earnings date of Coherus BioSciences Inc(CHRS) is 2024-03-06 Est..
Does Coherus BioSciences Inc(CHRS) pay dividends? If so, how much?
Coherus BioSciences Inc(CHRS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers